Поиск по репозиторию
Статья
The use of viral RNA polymerase inhibitors in combination with a fusion inhibitor in the treatment of patients with COVID-19: hypothesis [Применение ингибиторов вирусных РНК-полимераз в сочетании с ингибитором фузии в лечении пациентов с COVID-19: гипотеза]
2021
This review article considers the possibilities of combined antiviral therapy in the treatment of patients with COVID-19, based on the analysis of the mechanism of action of known antiviral drugs in the framework of the medical hypothesis. The potential effectiveness of the joint use of viral RNA polymerase inhibitors and a fusion inhibitor in this pathology is discussed. The review discusses the main representatives of these groups of drugs – ribavirin, riamilovir, umifenovir, favipiravir. The efficacy and safety profile of these drugs was analyzed, including the experience of their use in clinical trials conducted during the COVID-19 pandemic, as well as earlier work performed during the SARS and MERS epidemics. © 2020 Izdatel'stvo Meditsina. All rights reserved.
Цитирование
Похожие публикации
Версии
- 1. Version of Record от 2021-04-27
Метаданные
Название журнала
- Voprosy Virusologii
Том
- 65
Выпуск
- 3
Страницы
- 167-175
Ключевые слова
- favipiravir; riamilovir; ribavirin; RNA directed RNA polymerase inhibitor; umifenovir; virus fusion inhibitor; antivirus agent; enzyme inhibitor; antiviral therapy; Article; clinical trial (topic); coronavirus disease 2019; drug efficacy; drug mechanism; drug safety; human; pandemic; drug therapy; enzymology; epidemiology; metabolism; pandemic; Antiviral Agents; COVID-19; Enzyme Inhibitors; Humans; Pandemics; RNA-Dependent RNA Polymerase; SARS-CoV-2
Издатель
- FBSI Central Research Institute of Epidemiology of Rospotrebnadzor
Тип документа
- journal article
Тип лицензии Creative Commons
- CC
Правовой статус документа
- Свободная лицензия
Источник
- scopus
